Partnership goals to incorporate Aclarion’s surgical choice assist expertise inside ATEC’s AlphaInformatiX platform to higher inform spine surgical procedure
Aclarion’s Nociscan is the primary augmented intelligence platform to measure ache biomarkers within the lumbar spine to assist physicians establish the situation of power low again ache
BROOMFIELD, CO, Jan. 08, 2024 (GLOBE NEWSWIRE) — through NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare expertise firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians establish the situation of power low again ache, introduced as we speak that it has executed a strategic partnership settlement solidifying the beforehand signed non-binding Letter of Intent (“LOI”) with Alphatec Backbone, Inc., the wholly owned working subsidiary of Alphatec Holdings, Inc. (Nasdaq: ATEC).
Uniting the distinctive structural info powered by ATEC’s AlphaInformatiX platform with the progressive biomarker information that permits Aclarion’s Nociscan resolution to assist establish probably painful discs will present surgeons with unprecedented information on one platform. That platform will likely be designed to enhance scientific outcomes, whereas decreasing total procedural prices for sufferers with power low again ache (cLBP).
The settlement memorializes a multi-step strategic partnership during which ATEC and Aclarion have dedicated to work collectively to establish key opinion chief (KOL) surgeons to guage the Nociscan expertise. Suggestions from the surgeons will inform scientific evaluations designed to evaluate the utility of Nociscan along side EOS imaging, the inspiration of ATEC’s AlphaInformatiX platform. As optimistic synergies emerge, ATEC and Aclarion intend to co-market Nociscan in focused markets. In alternate for choose entry to ATEC’s surgeon community for the analysis and development of Nociscan, Aclarion has agreed to offer ATEC with sure unique distribution rights to incorporate Nociscan as a part of an built-in procedural resolution.
Pat Miles, Chairman and CEO of ATEC, commented, “Shifting from our beforehand signed LOI to this settlement in only a matter of weeks demonstrates our shared imaginative and prescient for the answer we are able to create collectively. We share an intent to maneuver by way of the phases of the settlement effectively and have already recognized inside leaders and assets to perform the primary section within the weeks to return. We consider within the significance of biochemical markers inside the remedy paradigm and by partnering with Aclarion, we are able to progress towards a mutual goal to combine and advance applied sciences that enhance the predictability and reproducibility of spine affected person care.”
Aclarion’s proprietary decision-support software, Nociscan, is the primary evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to spotlight if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers essential insights into the situation of a affected person’s low again ache, giving physicians readability to optimize remedy methods.
Aclarion’s revealed trials verify the comparative benefit of Nociscan in reaching differentiated surgical outcomes. In April 2023, a peer-reviewed publication demonstrated that the success fee at two years for discogenic low again ache surgical procedures was 85% for sufferers whose remedy technique was according to Nociscan-identified discs; a 22 proportion level enchancment over sufferers whose remedy technique was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0.07).1
“With ATEC, our Nociscan resolution can speed up progress by way of our acknowledged customary of care technique,” mentioned Brent Ness, CEO of Aclarion. “KOL advocacy, proof accumulation, and growing scan quantity mirrors what we now have agreed to within the first three phases of this settlement. The experience, attain, and assets of our companion give us super confidence that we are going to succeed. We consider that bundling Nociscan, which helps to establish the supply of ache in an analysis course of, with the essential scientific information supplied by ATEC’s AlphaInformatiX platform will result in higher outcomes – a thesis we intend to show within the upcoming months.”
Power low again ache is a worldwide healthcare drawback that impacts roughly 266 million folks worldwide. Standard imaging and diagnostics present precious structural info however are restricted in figuring out the supply of the pathogenic ache.
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages magnetic resonance spectroscopy (MRS), proprietary sign processing methods, biomarkers, and augmented intelligence algorithms to optimize scientific remedies. The Firm is first addressing the power low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By way of a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) information from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing methods extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers essential insights into the situation of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra info, please go to www.aclarion.com.
Alphatec Holdings, Inc., by way of its wholly owned subsidiaries, Alphatec Backbone, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical system firm devoted to revolutionizing the strategy to spine surgical procedure by way of scientific distinction. ATEC’s Natural Innovation MachineTM is targeted on creating new approaches that combine seamlessly with the Firm’s increasing AlphaInformatiX Platform to higher inform surgical procedure and extra safely and reproducibly obtain the objectives of spine surgical procedure. ATEC’s imaginative and prescient is to be the Customary Bearer in Backbone. For extra info, go to us at www.atecspine.com.
This press launch incorporates forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Alternate Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic details, similar to “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to various uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Alternate Fee. Readers are inspired to evaluate the part titled “Threat Elements” within the Firm’s Annual Report on Kind 10-Ok for the yr ended December 31, 2022, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Alternate Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
The knowledge acknowledged above was ready by Aclarion and displays solely the opinion of Aclarion. Nothing on this assertion shall be construed to indicate any assist or endorsement of Aclarion or any of its merchandise by ATEC.
Investor Contacts: Kirin M. Smith PCG Advisory, Inc. 646.823.8656 email@example.com
Media Contacts: Jodi Lamberti SPRIG Consulting 612.812.7477 firstname.lastname@example.org